Lymphoma Hub Press Release 2021: Q1

The Lymphoma Hub strives to inform real-world clinical practice by providing the latest trial and drug updates, key literature, and congress coverage.

In the first quarter of 2021, the Lymphoma Hub introduced a new educational theme of “The role of ctDNA in lymphoma management”. Through articles and expert interviews, the Lymphoma Hub has been providing expanded information to advance knowledge on this important topic.

Due to the current COVID-19 pandemic, the Lymphoma Hub has continued to carry out all functions in a virtual setting including the attendance of key conferences—the 3rd European CAR T-cell Meeting, the 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), and the National Comprehensive Cancer Network (NCCN) 2021 Virtual Annual Conference—where we provided live coverage via our Twitter channel, conducted interviews with experts, and published summary articles of key sessions and podcasts.

The Lymphoma Hub, founded in partnership with the European Lymphoma Institute and brought to you by Scientific Education Support, is dedicated to providing up-to-date, independent material for healthcare professionals. The Lymphoma Hub owes thanks to both existing and new sponsors, without whom the platform would not be possible. Last quarter, the Lymphoma Hub welcomed TG Therapeutics as a contributor and would like to extend a special thanks for their support going forward. The Lymphoma Hub also remains forever grateful to our ongoing supporters—Platinum supporter Bristol Myers Squibb, Gold supporters Roche/Genentech and Incyte, Silver supporter Novartis, and our Contributors Epizyme and Karyopharm Therapeutics.

For more information on the Lymphoma Hub, please visit lymphomahub.com. For media enquiries or to explore collaboration opportunities, please contact